83 results about "Inflammatory pain" patented technology

The present invention relates to N-palmitoyl ethanolamide for the treatment of inflammatory pain in combination with a non-steroidal anti-inflammatory drug, to the use of N-palmitoyl ethanolamide (referred to as palmitoyl ethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug for the treatment of inflammatory pain. Specifically, the present invention relates to palmitoyl ethanolamide for use in the treatment of inflammatory pain, in particular non-neurological inflammatory pain, in which palmitoyl ethanolamide is administered in combination or in combination with a non-steroidal anti-inflammatory drug as needed, in which the administration is separate, combined or simultaneous.

The present invention relates to a voltage-gated sodium channel Nav1.8 selective inhibitor and the use thereof in the preparation of a related drug. The drug is used for treating diseases responsive to the inhibition of voltage-gated sodium channel NaV1.8, such as chronic pain, enterodynia, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, post-operative pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough or arrhythmia. Specifically, the present invention relates to a compound as shown in formula (X), and an isomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof.

The present invention is directed to novel compounds that inhibit Nav1.8 sodium channels, methods of making, and methods of using thereof. The present disclosure is further directed to administering the disclosed compounds as therapeutic solutions for chronic pain, primary pain, idiopathic pain, gastrointestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer-related pain, idiopathic pain, postoperative pain, visceral pain, multiple sclerosis, Summer-Marr-Tuff syndrome, incontinence, pathological cough, or arrhythmia to a subject in need thereof.

The invention belongs to the technical field of pharmaceutical preparations, and particularly discloses a compound bear gall pain-relieving gel as well as a preparation method and application thereof. The compound bear gall pain-relieving gel comprises the following components in percentage by mass: 15-25% of a traditional Chinese medicine composition, 2.5-3.5% of a matrix, 7-13% of a humectant, 1-10% of a penetration enhancer and a proper amount of a pH regulator. The invention discloses a compound bear gall pain-relieving gel as well as a preparation method and application thereof. The compound bear gall pain-relieving gel has a remarkable treatment effect on inflammatory pain and can quickly relieve pain and relieve swelling, the gel dosage form is convenient to smear and can directly reach a focus, and a safe, efficient and convenient new choice is provided for treatment of the inflammatory pain.

The application discloses application of hen egg white lysozyme (HEL) in relieving chronic pain, and experiment results show that HEL significantly and selectively relieves inflammatory pain, neuropathic pain and static mechanical allodynia induced by chemotherapy pain. Meanwhile, experiments show that HEL causes the expression of a mechanical sensitivity ion channel TACAN in the PRKN / TACAN pathway on the cell membrane to be reduced by up-regulating the expression of PRKN protein of primary sensory neurons in the dorsal root ganglion, thereby significantly inhibiting static mechanical allodynia. The application firstly finds that HEL has the effect of relieving static mechanical allodynia and a deep mechanism, and the source of HEL is non-toxic and safe, and has potential application value in preparation of medicines for preventing, treating and relieving chronic pain, and has great clinical significance.

This disclosure presents systems and methods for baroreflex activation therapy (BAT) to regulate inflammation by modulating autonomic nervous system activity. Electrical stimulation is delivered to one or more baroreceptors, and real-time physiological signals are monitored, including inflammatory biomarkers (e.g., TNF-α, IFN-γ, IL-1, IL-6, IL-12, CRP) and autonomic parameters such as heart rate variability (HRV). A closed-loop feedback module analyzes biomarker fluctuations and autonomic balance changes and dynamically modifies stimulation parameters, including amplitude, pulse width, frequency, and duty cycle, to suppress systemic inflammation and restore autonomic balance. In certain embodiments, multi-channel stimulation architectures and AI-driven algorithms or machine learning models analyze biomarker trends and historical patient response patterns to optimize therapy. The disclosed BAT systems and methods may be used to treat inflammatory diseases, autoimmune disorders, cancer progression, chronic inflammatory pain conditions, arrhythmias associated with inflammation, and metabolic dysfunction.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The invention relates to an application of a halophenol compound 2, 4 ', 5'-trihydroxy-5, 2 '-dibromo benzophenone in preparation of an analgesic drug. Experiments prove that the compound has a definite analgesic effect, can significantly inhibit mouse writhing reaction induced by acetic acid and II-phase inflammatory pain induced by formalin, and prolongs the thermal stimulation tail retraction incubation period, and the effect is superior to that of aspirin. Furthermore, in a nitroglycerin-induced migraine rat model, the compound can effectively improve behavioral symptoms and brain tissue pathological damage and remarkably regulate key index levels of CGRP, PGE2, ET-1, IL-1beta, IL-6, TNF-alpha, 5-HT and the like in plasma, which shows that the compound can be applied to preparation of analgesic drugs, preparation of drugs for treating migraine, preparation of drugs for treating migraine and the like. The invention particularly has important application value in medicines for preventing and / or treating migraine.

The invention relates to a TRPV1 / URAT1 dual inhibitor containing a naphthalene ring and a 2, 2-difluorobenzodioxole structure and an application of the TRPV1 / URAT1 dual inhibitor. The invention relates to a TRPV1 / URAT1 dual inhibitor containing a naphthalene ring and a 2, 2-difluorobenzodioxole structure, and the structural formula of the TRPV1 / URAT1 dual inhibitor is as follows: # imgabs0 #. The compound is unique and novel in structure, a preparation method of the compound is researched and provided, the compound has high inhibitory activity as a TRPV1 / URAT1 dual inhibitor, IC50 to TRPV1 is smaller than or equal to 100 nM, IC50 to URAT1 is smaller than or equal to 1 mu M, and inhibitory activity IC50 to an hERG channel is larger than 30 mu M; the traditional Chinese medicine composition has an excellent treatment effect on hyperuricemia, gout, inflammatory pain and the like, also has a better analgesic effect, and can be used as an analgesic medicine, a medicine for treating gout or hyperuricemia and the like.

The invention belongs to the technical field of medicine, and discloses application of SHLP2 in preparation of medicine for relieving and treating acute and chronic inflammatory pain, and the amino acid sequence of SHLP2 polypeptide is MGVKFFTLSTRFFPSVQRAVPLWTNS. After the SHLP2 polypeptide is treated in an intrathecal (5 [mu] g / 10 [mu] g / 20 [mu] g) injection mode, the SHLP2 polypeptide shows a good treatment effect in an acute inflammation pain model induced by formalin and capsaicin and a chronic inflammation pain model induced by carrageenan and a complete Freund's adjuvant. The SHLP2 is utilized to target a mitochondrial genome, the effect of relieving acute and chronic inflammatory pain is achieved in a central sheath injection mode, and a target different from a traditional analgesic drug can be searched for treatment of the acute and chronic inflammatory pain.

Provided is a cyclic peptide derivative composition for treating or preventing neuropathic pain and / or inflammatory pain. The present disclosure relates to compositions comprising a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof for treating or preventing neuropathic and / or inflammatory pain. The present disclosure also relates to a method for treating or preventing neuropathic pain and / or inflammatory pain comprising administering a composition comprising a compound or a pharmaceutically acceptable salt thereof. The technology provided by the present disclosure can be used in a cyclic peptide derivative for modulating the activity of nervous system cells and a method for producing the same.

The present invention relates to compounds of formula (I) and pharmaceutical compositions comprising these compounds. The compounds provided herein can be used as prostaglandin E2 (PGE2) EP4 receptor antagonists, which makes them very useful for therapy, particularly for the treatment or prevention of cancer, neovascular eye disease, inflammatory pain or inflammatory diseases such as multiple sclerosis, rheumatoid arthritis or endometriosis. #imgabs0#

The utility model discloses a double-foot balance pain measurement test mouse cage which comprises a bottom plate, a base plate is fixedly connected to the bottom plate, two flat pedals are symmetrically arranged on the upper surface of the base plate, and pressure sensors are arranged between the two flat pedals and the base plate respectively. Two vertical plates are symmetrically fixed to the upper surface of the bottom plate and used for supporting the left foot and the right foot of a mouse respectively, an inclined pedal is fixed between the two vertical plates and used for supporting the front foot of the mouse, the opposite faces of the two vertical plates are each provided with a baffle, and a plurality of guide columns are fixed to the side wall of each baffle. By means of the two flat pedals symmetrically arranged on the bottom plate and the base plate, standing support is provided for a mouse, the built-in pressure sensors can monitor and record pressure distribution of the rear feet of the mouse in real time, and therefore the inflammatory pain state of the rear feet of the mouse can be accurately reflected, and the mouse can be conveniently taken out. And the accuracy of experimental data is improved.

The present invention relates to a sulfonylurea derivative and medical uses thereof, specifically relating to the sulfonylurea derivative shown in general formula (I), a preparation method thereof, a pharmaceutical composition containing same, and a use of same for treating diseases and disorders affected by neuronal damage, for example: cerebral stroke, brain damage, neuropathic pain, migraines, inflammatory pain, chronic pain, or depression. The definition of each group in the general formula (I) is the same as that in the description.

This invention discloses the application of a polypeptide in inhibiting inflammatory pain, belonging to the field of biomedicine. The polypeptide is Mexneurin-3 (Mx-3), one of three Mexneurin polypeptides formed by the cleavage of ProMexneurin, a protein precursor found in the mammalian central nervous system, by proprotein convertase. This invention reveals that Mx-3, as an endogenous polypeptide, has significant analgesic effects, inhibiting both acute and chronic inflammatory pain with fewer side effects and greater safety. This invention also elucidates the analgesic mechanism of Mx-3, finding that it upregulates diacylglycerol (DAG) levels in the spinal cord and activates protein kinase C (PKC). The application of Mx-3 in inhibiting inflammatory pain provided by this invention can be used to develop safer and more effective novel analgesics, providing new ideas and references for the treatment of inflammatory pain.

The invention relates to the field of traditional Chinese medicine external preparations, in particular to traditional Chinese medicine external liniment medicinal liquor for dispelling wind, eliminating dampness, activating blood and diminishing swelling, which comprises the following components in parts by weight: 5-15 parts of rheum officinale, 3-10 parts of arisaema consanguineum schott, 8-20 parts of mangnolia officinalis, 6-18 parts of liquorice, 5-12 parts of lotus powder, 10-25 parts of turmeric, 8-20 parts of golden cypress, 6-15 parts of pericarpium citri reticulatae, 5-12 parts of safflower, 8-18 parts of ligusticum wallichii, 10-25 parts of teasel root, 15-30 parts of eucommia ulmoides and 12-28 parts of rhizoma drynariae. The medicinal liquor is prepared from the following raw materials in parts by weight: 3-9 parts of dragon's blood, 8-20 parts of myrrh, 2-6 parts of pearl powder, 5-15 parts of mung bean seed-coat, 1-4 parts of borneol and 200-500 parts of Baijiu. Based on the innovative concept of eliminating evil, strengthening body resistance and multi-target cooperation, four functional components of expelling wind-damp, promoting blood circulation to remove blood stasis, strengthening tendons and bones and promoting tissue regeneration to heal sores are integrated, the limitation of traditional medicinal liquor is broken through through toxic effect balance compatibility and a gradient permeation process, and the externally applied medicinal liquor can improve local blood circulation, relieve inflammation pain and improve the curative effect of the traditional medicinal liquor. In addition, bone metabolism balance can be adjusted, tissue repair is promoted, and a novel treatment choice is provided for patients with chronic osteoarticular diseases and compound trauma.

The inventor has synthesized 2 '-O > 2-methoxyethyl modified FXYD2-LASO (FXYD2-LASO-gapmer) and injects the 2'-O > 2-methoxyethyl modified FXYD2-LASO and the 2 '-O > 2-methoxyethyl modified FXYD2-LASO-gapmer into the vein, and an application way with relatively small invasiveness is provided. Intravenous administration of the FXYD2 optimized antisense oligonucleotide (LASO) with MOE, compared to intrathecal administration, allows for a long-term effect on pain. The inventors have proven this long term effect on neuropathic pain in spinal nerve ligation (SNL) rat models and inflammatory pain in complete Freund's adjuvant (CFA) induced rat models. Thus, the present invention relates to antisense oligonucleotides targeting FXYD2 for use in the treatment of pain wherein the antisense oligonucleotides are administered intravenously.

The present invention relates to a morphinan-type compound, a preparation method therefor, a composition thereof and the use thereof. Specifically disclosed is a compound I or a pharmaceutically acceptable salt thereof. The morphinan-type compound of the present invention has one or more of the following effect advantages: (1) a relatively high binding affinity for an opioid receptor; (2) a significant agonistic effect on KOR and MOR; (3) good selectivity for a κ receptor; and (4) a good therapeutic effect on inflammatory pain (for example, rapid onset of action or significant analgesic effect).

A transdermal patch for delivering lidocaine for pain relief comprises a backing layer, an adhesive layer, and a composition containing lidocaine in an amount ranging from about 1% to about 10% by weight and heparin as a non-anticoagulant permeation enhancer in an amount ranging from about 1% to about 50% by weight. The heparin enhances permeation of lidocaine through the skin without exerting systemic anticoagulant effects by temporarily disrupting lipid bilayers in the stratum corneum to create microchannels for increased diffusion of lidocaine molecules. The patch provides effective relief for multiple pain types including neuropathic pain, inflammatory pain, ischemic pain, post-surgical pain, nociplastic pain, mechanical pain, and compressive pain. The transdermal patch is configured to provide sustained release of lidocaine for periods ranging from about 8 hours to about 24 hours, reducing pain by at least 50% with minimal systemic absorption.

The present invention relates to a synergistic admixture of Gabapentin and Ketoprofen, preferably Ketoprofen Lysine, to a pharmaceutical composition comprising said admixtures and to the use of said admixtures or pharmaceutical compositions in the treatment of acute or chronic pain, in particular in the treatment of neuropathic or inflammatory pain.

To provide a pharmaceutical for the prevention or treatment of pain associated with nociceptive pain, inflammatory pain, or neuropathic pain.SOLUTION: A pharmaceutical for the prevention or treatment of pain associated with nociceptive pain, inflammatory pain, or neuropathic pain, comprises, as an active ingredient, 5-[4-(2-iodobenzoylamino)phenyl]-1H-naphtho[1,2-b][1,4]diazepine-2,4(3H,5H)-dione or a pharmaceutically acceptable salt thereof, in which no effect is recognized on driving ability or on machinery operating ability, or no effect is recognized on automobile driving ability, or limitation of administration is not required even for patients engaged in dangerous machinery operation including automobile driving, or the pharmaceutical can be administered even to patients engaged in dangerous machinery operation including automobile driving.SELECTED DRAWING: Figure 1

The application relates to the technical field of pharmaceutical chemistry, and discloses a flurbiprofen ester enantiomer prodrug compound, a preparation method thereof, a pharmaceutical composition and purposes, the compound is (R)-AF377 or (S)-AF377, is formed by covalently connecting a carboxyl of (R)-flurbiprofen, (S)-flurbiprofen and a phenolic hydroxyl of acetaminophen through an ester bond, corresponding chiral carbons are R configuration and S configuration respectively, and structures are shown in formula (I) and formula (II). The application further provides a preparation method of the compound, a pharmaceutical composition containing the compound and purposes of the compound in pain, inflammation or fever treatment. The compound has high optical purity, releases an active ingredient in the liver, (S)-AF377 has synergistic anti-inflammatory analgesic activity, (R)-AF377 has independent analgesic activity, can reduce side effects of single drug use, improves bioavailability, and provides a new drug selection for treatment of mild to moderate inflammatory pain.

The invention discloses a twin drug with analgesic effect and application thereof, the twin drug is formed by connecting a drug A and a drug B through a chemical bond, the drug A is a TRPV1 agonist, and the drug B is lipoic acid, pregabalin, gabapentin, melogabalin or clinigabalin. Meanwhile, the invention also comprises a preparation method of the twin drug, and application of the twin drug or pharmaceutically acceptable salts and compositions thereof in preparation of drugs for preventing and treating pains or nervous system diseases. The twin drug can significantly improve the water solubility of the TRPV1 agonist, has a long-acting analgesic effect on different types of pains such as inflammatory pains and neuralgia, and has an analgesic effect superior to that of a composition of the two components and then superior to that of a single component. Meanwhile, twin drugs show a more lasting analgesic effect and have a good application prospect.

Disclosed herein are methods and compositions for treating a disease or disorder in a subject in need thereof. The methods may include administering to the subject a therapeutically effective amount of a GPR37 agonist. The disease or disorder may be selected from inflammation, inflammatory pain, chronic pain, viral infection, bacterial infection, malaria, sepsis, or a combination thereof.

The invention belongs to the technical field of biological medicine, and particularly relates to synthesis and application of an oligopeptide compound. According to the invention, a plurality of methods are adopted to carry out structure optimization on WvVf-OCH3, and a series of WvVf-OCH3 structural optimization mutants with a relatively good inhibition effect on nAChRs are obtained. The mutant has excellent performance in the aspects of safety, stability and in-vivo efficacy, and has definite efficacy and development potential in the aspects of relieving muscle tension, removing wrinkles and relieving inflammatory pain. The WvVf-OCH3 mutant can be used as a candidate medicine for treating symptoms such as muscle tension, spasm and pain, or can be used as an active raw material of a medical beauty product with a wrinkle removing function.

Disclosed is a composition for preventing, ameliorating or treating arthritis, which contains a hydrangea crassifolia extract or hydrangeol as an active ingredient. The present invention not only inhibits the expression of MMP-1 and MMP-9, increases the synthesis of type II procollagen, and alleviates inflammation, but also has an effect of preventing, ameliorating or treating arthritis by inhibiting inflammatory pain.

The invention relates to application of anacycline A in preparation of analgesic drugs, in particular to an anacycline A compound separated from anacycline roots. The compound can be applied to analgesic drugs with inhibition effects on transient receptor potential cation channel subfamily M member 8 (TRPM8), a voltage-gated potassium ion channel 1.2 (Kv1.2), a voltage-gated potassium ion channel 1.3 (Kv1.3), transient receptor potential cation channel protein 6 (TRPC6) and a voltage-gated calcium ion channel 2.1 (Cav2.1), in particular to drugs for neuropathic pain, traumatic pain or inflammatory pain. The compound anacycline A can be combined with a plurality of analgesia-related targets, so that a synergistic effect is generated, the treatment effect is enhanced, and meanwhile, side effects and drug resistance are reduced.

The application discloses an indolone compound and a pharmaceutical composition and application thereof, and has a molecular structure as follows: the indolone compound has double activities of analgesia and antioxidation, can be used as an analgesic with an antioxidation function, and has application potential in inflammatory pain care.

The invention relates to the technical field of medicines, and particularly discloses application of 9-anthraformic acid in preparation of a non-addictive peripheral analgesic medicine. It is proved for the first time that 9-anthracene formic acid has a remarkable analgesic effect and can effectively relieve inflammatory pain, the action target is a peripheral part, central side effects such as addiction and respiratory depression of traditional opioid analgesic are avoided, gastrointestinal injury, cardiovascular risk and curative effect capping effect of non-steroidal anti-inflammatory drugs are also overcome, and the 9-anthracene formic acid can be applied to preparation of anti-inflammatory drugs. Animal experiments prove that the analgesic effect of the compound is comparable with that of classical opioid drug morphine, and a brand new candidate drug and an application direction are provided for developing novel non-addiction analgesic drugs.

The application provides a kind of cartilage polypeptide composition and its preparation method, the cartilage polypeptide 30-45%, auxiliary agent 10-25%, growth agent 3-8%, slow-release agent 2-9%, the balance is water, the application will cartilage polypeptide, auxiliary agent, growth agent and slow-release agent several ingredients scientific compatibility, preparation has the composition of protecting cartilage tissue, anti-inflammatory pain, effectively increase bone density effect, improve synovial tissue, there is no rebound ineffective condition after drug withdrawal.